Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 18/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 6/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 5/20 | 1.00 |
| ▸ | TMPRSS4 | Q9NRS4 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | IKBKB | O14920 | 1/20 | 0.68 |
| ▸ | CHUK | O15111 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MYLK | Q15746 | 1/20 | 0.68 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23675377 | 0.91 | P2RX1 (0.84) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| Salfluverine SCHEMBL2700016 | 0.88 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4 | |
| SCHEMBL2698258 | 0.86 | P2RX1 (0.75) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL30665186 | 0.86 | P2RX1 (0.75) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL4928355 | 0.84 | P2RX1 (0.76) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL10797383 | 0.84 | P2RX1 (0.73) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL130439 | 0.84 | P2RX1 (0.81) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL3497353 | 0.84 | P2RX1 (0.72) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL3284516 | 0.83 | P2RX1 (0.71) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL131701 | 0.83 | P2RX1 (0.71) | P2RX1P2RX7P2RX4TMPRSS4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | claimed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | claimed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | claimed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | claimed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | claimed |
| WO-2021086567-A1 | COMPOUNDS AND METHODS FOR POTENTIATING COLISTIN ACTIVITY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-05-06 | — | — | WO | disclosed |
| US-9266872-B2 | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-02-23 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | P2RX1 2484/4885P2RX7 2360/4885P2RX4 3324/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | P2RX1 2927/4885P2RX7 2720/4885P2RX4 3704/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885P2RX7 973/4885P2RX4 2695/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885P2RX7 973/4885P2RX4 2695/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2425/4885P2RX7 2267/4885P2RX4 3298/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2389/4885P2RX7 2289/4885P2RX4 3242/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | P2RX1 4273/4885P2RX7 4289/4885P2RX4 3330/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | P2RX1 2316/4885P2RX7 1605/4885P2RX4 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.